1. Home
  2. |Insights
  3. |Government Charged With Knowledge of Unapproved Subcontractors Listed on Invoices

Government Charged With Knowledge of Unapproved Subcontractors Listed on Invoices

Client Alert | 1 min read | 10.02.19

In URS Federal Services, Inc. (Sept. 3, 2019), the ASBCA found on summary judgment that the government’s 2017 claim to recover $698,685 in allegedly unallowable direct subcontractor costs was time-barred by the CDA’s six-year statute of limitations because the claim accrued in 2006, when the government paid URS’s invoices that included those costs. In arguing that it could only have “known” about the basis of its claim in 2012 when URS resubmitted its final indirect cost rate proposal for FY 2006, the government alleged that URS: (1) failed to receive contractual approval to subcontract, and (2) lacked adequate documentation (now) demonstrating that the costs at issue were incurred and allocable to the contract. Regarding the first basis, the Board found that the invoices listing the allegedly unapproved subcontractors demonstrated the government had knowledge that URS was using them when the government paid the invoices. The Board declined to grant summary judgment on the documentation issue. 

Insights

Client Alert | 7 min read | 09.14.26

AI in Life Sciences: Ten Legal Considerations and Risks of AI Use in Drug Discovery and Development

Over the past several years, the biopharmaceutical industry has embraced artificial intelligence and machine learning (AI/ML) in near lockstep with the pace of AI/ML innovations. Today, industry leaders are using AI/ML to, among other things: discover and assess biological pathways, target chemical structures and sequences; design proteins; model pre-clinical and clinical trials; recruit and screen potential patient populations; evaluate clinical trial results and biomarker data; prepare regulatory filings; and manage supply chains. Deployment of new AI/ML models promises extraordinary advances in pharmaceutical development. However, as with any technological and scientific advances, the use of AI/ML also poses substantial legal risks that life sciences companies need to consider and proactively manage. ...